Literature DB >> 25239598

With regard to our manuscripts on the commercial saliva substitute, Oralbalance®--its formula has been changed.

Yuko Sugiura1, Yoshihiko Soga, Ichiro Tanimoto, Susumu Kokeguchi, Sachiko Morishige-Nishide, Kotoe Itami-Kono, Kanayo Takahashi, Nobuharu Fujii, Fumihiko Ishimaru, Mitsune Tanimoto, Kokoro Yamabe, Soichiro Tsutani, Fusanori Nishimura, Shogo Takashiba.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 25239598     DOI: 10.1007/s00520-014-2432-8

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  4 in total

1.  A double-blind, crossover study of Biotène Oralbalance and BioXtra systems as salivary substitutes in patients with post-radiotherapy xerostomia.

Authors:  S A Shahdad; C Taylor; S C Barclay; I N Steen; P M Preshaw
Journal:  Eur J Cancer Care (Engl)       Date:  2005-09       Impact factor: 2.520

2.  A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer.

Authors:  P Warde; B Kroll; B O'Sullivan; J Aslanidis; E Tew-George; J Waldron; W Maxymiw; F F Liu; D Payne; B Cummings
Journal:  Support Care Cancer       Date:  2000-05       Impact factor: 3.603

3.  Total bacterial counts on oral mucosa after using a commercial saliva substitute in patients undergoing hematopoietic cell transplantation.

Authors:  Yuko Sugiura; Yoshihiko Soga; Kokoro Yamabe; Soichiro Tsutani; Ichiro Tanimoto; Hiroshi Maeda; Susumu Kokeguchi; Nobuharu Fujii; Fumihiko Ishimaru; Mitsune Tanimoto; Fusanori Nishimura; Shogo Takashiba
Journal:  Support Care Cancer       Date:  2009-12-05       Impact factor: 3.603

4.  Antimicrobial effects of the saliva substitute, Oralbalance, against microorganisms from oral mucosa in the hematopoietic cell transplantation period.

Authors:  Yuko Sugiura; Yoshihiko Soga; Ichiro Tanimoto; Susumu Kokeguchi; Sachiko Nishide; Kotoe Kono; Kanayo Takahashi; Nobuharu Fujii; Fumihiko Ishimaru; Mitsune Tanimoto; Kokoro Yamabe; Soichiro Tsutani; Fusanori Nishimura; Shogo Takashiba
Journal:  Support Care Cancer       Date:  2008-01-16       Impact factor: 3.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.